Pricing Log in Create free account

Grifols, S.A. (GRFS) vs Nasus Pharma Ltd. (NSRX)

Grifols, S.A. and Nasus Pharma Ltd. are both Drug Manufacturers General companies. Grifols, S.A. is the larger, with a market value of $2.0B against $37.1M — 52.6× the size. Across the 5 metrics below, Nasus Pharma Ltd. leads on 3 and Grifols, S.A. on 2.

Valuation

Metric GRFS NSRX Drug Manufacturers General median
P/E 8.46 — 24.54
P/S 0.60 — 3.39
P/B 0.56 n/m 5.00
Price to free cash flow 7.03 n/m 16.55
EV/EBITDA 7.90 n/m 13.82
EV/Sales 1.77 n/m 4.03
Earnings yield 11.82% — 2.98%
Free cash flow yield 14.23% 0.00% 4.46%

Profitability

Metric GRFS NSRX Drug Manufacturers General median
Gross margin 37.45% — 72.77%
Operating margin 16.43% — 18.77%
Net margin 5.54% — 8.27%
Free cash flow margin 0.00% 0.00% 17.18%
Return on equity 0.00% 0.00% 5.87%
Return on assets 0.00% 0.00% 2.57%
Return on invested capital 0.00% 0.00% 6.11%

Growth

Metric GRFS NSRX Drug Manufacturers General median
Revenue growth (TTM) 16.03% — 6.66%
EPS growth (last fiscal year) 168.00% (231.82%) 21.81%
Revenue growth, 5-year CAGR 6.89% — 4.75%
Net income growth, 5-year CAGR (8.43%) — 0.00%

Health

Metric GRFS NSRX Drug Manufacturers General median
Debt to equity 1.17 0.00 0.63
Current ratio 2.37 8.77 1.32
Net debt to EBITDA 5.19 0.26 1.15

Dividend

Metric GRFS NSRX Drug Manufacturers General median
Dividend yield 1.24% — 2.33%
Payout ratio 0.10 — 0.59

Size

Metric GRFS NSRX Drug Manufacturers General median
Market cap 1.95b 37.06m 123.73b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack